Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PPP5C | P53041 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.30 |
| ▸ | TFPI2 | P48307 | 2/20 | 0.30 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.30 |
| ▸ | NPY4R | P50391 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21195851 | 0.85 | — | — | |
| SCHEMBL505180 | 0.85 | — | — | |
| SCHEMBL20760369 | 0.82 | CHRNB2 (0.45) | SMN1; SMN2ALDH1A1NPC1NPSR1HSD17B10 | |
| SCHEMBL504701 | 0.77 | PPP5C (0.40) | SMN1; SMN2PPP5C | |
| SCHEMBL3210127 | 0.76 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1HPGDNPC1NPSR1 | |
| SCHEMBL20680545 | 0.76 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1HPGDNPC1NPSR1 | |
| SCHEMBL2854416 | 0.76 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1HPGDNPC1NPSR1 | |
| SCHEMBL20680182 | 0.76 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1HPGDNPC1NPSR1 | |
| Hydrochloric Acid SCHEMBL2973089 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1HPGDNPC1NPSR1 | |
| Hydrochloric Acid SCHEMBL2973085 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1HPGDNPC1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-1562612-B1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE FOR USE IN THE TREATMENT OR PROPHLAXIX OF PANCREATIC CANCER | ASTRAZENECA AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-7462623-B2 | Quinazoline derivatives as Src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | disclosed |
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | SRC, TEK, FLT4 | SMN1; SMN2 4497/4885ALDH1A1 4169/4885HPGD 1595/4885 |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | SRC, PTPN4, PTPN1 | SMN1; SMN2 3122/4885ALDH1A1 4645/4885HPGD 4369/4885 |
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | SRC, CHUK, CTTN | SMN1; SMN2 3127/4885ALDH1A1 2143/4885HPGD 1728/4885 |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | SRC, ABL1, ERBB2 | SMN1; SMN2 3352/4885ALDH1A1 3374/4885HPGD 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.